All In MedTech

Device Trial Radar · NCT05209828

Post-market Clinical Follow-up of Pfmmedical Ports

Prospective, Monocentric Observational Study on the Clinical Use and Patient Satisfaction of Pfmmedical Implantable Vascular Access Ports

Last checked: Nov 20, 2026Latest source record: Apr 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

149

Actual

Start

Apr 13, 2022

Primary completion

Mar 9, 2023

Study completion Mar 9, 2023

Sponsor

Lead sponsor
pfm medical gmbhNot on our public-company list
Sponsor type
Industry
First posted
Jan 27, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, monocentric, non-randomised, observational post-market clinical follow-up study in Germany to obtain post-market information on the pfmmedical ports with a follow-up (FU) of 6 months. The focus is on patient reported satisfaction, clinical application, and complication rates.

Conditions

  • Vascular Access Port
  • Patient Satisfaction

Interventions

  • pfmmedical implantable vascular access portsDevice

    Implantion of an implantable vascular access port which facilitates repeated vascular access intended for the delivery of medications, intravenous fluids, parenteral nutrition solutions or blood products and blood sampling using a Huber needle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patients satisfactionTime frame: 6 months after port implantation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Heidelberg University Hospital

    Heidelberg, Baden-Wurttemberg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.